151 related articles for article (PubMed ID: 33169427)
1. Determination of the pharmacokinetic-pharmacodynamic cut-off values of marbofloxacin in horses to support the establishment of a clinical breakpoint for antimicrobial susceptibility testing.
Bousquet-Mélou A; Schneider M; El Garch F; Broussou DC; Ferran AA; Lallemand EA; Triboulloy C; Damborg P; Toutain PL
Equine Vet J; 2021 Sep; 53(5):1047-1055. PubMed ID: 33169427
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of marbofloxacin against Coagulase-negative staphylococci, Staphylococcus aureus and Mycoplasma agalactiae pathogens in goats.
Serrano-Rodríguez JM; Fernández-Varón E; Rodríguez CMC; Andrés-Larrea MIS; Rubio-Langre S; de la Fe C; Dova SW; Bhardwaj P; Sidhu PK; Litterio NJ; Lorenzutti AM
Res Vet Sci; 2023 Jun; 159():1-10. PubMed ID: 37060837
[TBL] [Abstract][Full Text] [Related]
3. VetCAST Method for Determination of the Pharmacokinetic-Pharmacodynamic Cut-Off Values of a Long-Acting Formulation of Florfenicol to Support Clinical Breakpoints for Florfenicol Antimicrobial Susceptibility Testing in Cattle.
Toutain PL; Sidhu PK; Lees P; Rassouli A; Pelligand L
Front Microbiol; 2019; 10():1310. PubMed ID: 31244816
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics/pharmacodynamics cut-off determination for fosfomycin using Monte Carlo simulation in healthy horses.
Kuroda T; Minamijima Y; Niwa H; Mita H; Tamura N; Fukuda K; Toutain PL; Ohta M
J Vet Med Sci; 2024 Apr; 86(4):413-420. PubMed ID: 38346727
[TBL] [Abstract][Full Text] [Related]
5. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic cutoff values for benzylpenicillin in horses to support the establishment of clinical breakpoints for benzylpenicillin antimicrobial susceptibility testing in horses.
Lallemand EA; Bousquet-Mélou A; Chapuis L; Davis J; Ferran AA; Kukanich B; Kuroda T; Lacroix MZ; Minamijima Y; Olsén L; Pelligand L; Portugal FR; Roques BB; Santschi EM; Wilson KE; Toutain PL
Front Microbiol; 2023; 14():1282949. PubMed ID: 37954237
[TBL] [Abstract][Full Text] [Related]
7. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
Dorey L; Pelligand L; Lees P
BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
[TBL] [Abstract][Full Text] [Related]
8. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
Drusano GL; Preston SL; Hardalo C; Hare R; Banfield C; Andes D; Vesga O; Craig WA
Antimicrob Agents Chemother; 2001 Jan; 45(1):13-22. PubMed ID: 11120938
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of marbofloxacin in horses.
Bousquet-Melou A; Bernard S; Schneider M; Toutain PL
Equine Vet J; 2002 Jul; 34(4):366-72. PubMed ID: 12117108
[TBL] [Abstract][Full Text] [Related]
10. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
Rubio-Langre S; Aguilar-Sola S; Lorenzutti AM; San Andrés MI; De Lucas JJ; Litterio NJ
J Vet Pharmacol Ther; 2018 Dec; 41(6):861-870. PubMed ID: 30020535
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.
Boothe DM; Boeckh A; Simpson RB; Dubose K
J Vet Intern Med; 2006; 20(6):1297-306. PubMed ID: 17186841
[TBL] [Abstract][Full Text] [Related]
13. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes.
Labreche MJ; Frei CR
Am J Health Syst Pharm; 2012 Nov; 69(21):1863-70. PubMed ID: 23111670
[TBL] [Abstract][Full Text] [Related]
14. The disposition of trimethoprim and sulfadiazine in neonatal foals after intravenous administration.
Ekstrand C; Nostell K; Gehring R; Bondesson U; Bröjer J
Vet Med Sci; 2022 May; 8(3):1065-1071. PubMed ID: 35152563
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal.
Toutain PL; Pelligand L; Lees P; Bousquet-Mélou A; Ferran AA; Turnidge JD
J Vet Pharmacol Ther; 2021 Mar; 44(2):172-200. PubMed ID: 33089523
[TBL] [Abstract][Full Text] [Related]
16. Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.
Haritova AM; Rusenova NV; Parvanov PR; Lashev LD; Fink-Gremmels J
Antimicrob Agents Chemother; 2006 Nov; 50(11):3779-85. PubMed ID: 16940071
[TBL] [Abstract][Full Text] [Related]
17. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
Frei CR; Wiederhold NP; Burgess DS
J Antimicrob Chemother; 2008 Mar; 61(3):621-8. PubMed ID: 18252694
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
Andes D; Craig WA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease.
Vallé M; Schneider M; Galland D; Giboin H; Woehrlé F
J Vet Pharmacol Ther; 2012 Dec; 35(6):519-28. PubMed ID: 22126438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
